ClinicalTrials.gov
public full text
Public Domain
Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism
Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ziprasidone vs Standard Therapy for Agitated Patients in the ED#1172774
- Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction#884398
- Peer Support in Alcohol Dependence#898940
- Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study#1127532
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder#825049
Record · ID 1112088
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive